PRR Project

GeneLink

On this page

Project sheet
Beneficiaries
Procurement
Applications
Geographic distribution Section containing graph.

Project sheet

Name

GeneLink

Total project amount

30 thousand €

Amount paid

5 thousand €

Non-refundable funding

30 thousand €

Loan funding

0 €

Start date

01.06.2025

Expected end date

31.12.2025

Dimension

Digital Transition

Component

Businesses 4.0

Investment

Digital Transition for Businesses

Operation code

21/C16-i02/2025.P22329

Summary

A BioGHP é especializada no desenvolvimento de soluções tecnológicas para saúde, incorporando tecnologias transformadoras como IA e blockchain. A sua aplicação BioWallet, para pacientes e profissionais de saúde, permite a angariação, gestão e partilha de informações de saúde, e o seu produto BioNode promove a interoperabilidade entre sistemas de informação de saúde. Para suporte à prestação de cuidados de saúde e investigação científica, a BioGHP fornece aplicações verticais de IA e acesso a dados de saúde validados por médicos.O próximo produto, GeneLink, visa universalizar a integração e correlação de dados clínico-genómicos e surge como resposta à relevância crescente da Medicina Genómica e de Precisão e aos requisitos de intervenientes-chave: pacientes, médicos e profissionais de saúde, e data scientists.O projeto tem como objetivo desenvolver, pilotar e validar o GeneLink (TRL5), e preparar a evolução para níveis superiores de TRL, até ao lançamento e exploração comercial.

Beneficiaries Applications Procurement Geographic distribution

Beneficiaries

Within the scope of the Recovery and Resilience Plan, two types of beneficiaries are responsible for carrying out the projects and using the funding provided. Due to their similar role, the reference to these two types of beneficiaries has been simplified and unified under the term "Beneficiary".
The two types are::

Direct Beneficiaries are those whose funding and projects to implement are part of the Recovery and Resilience Plan that has been negotiated and approved by the European Union;
Final Beneficiaries are those whose funding and projects to implement are approved following a selection process through Calls for Applications.

Call for applications

As part of the Call for Applications, submissions are requested to select the projects and final beneficiaries to whom funding will be awarded. Specific selection criteria are defined for each call, which must be reflected in the applications submitted and assessed.

The project is appraised on the basis of its compliance with the selection criteria laid down in the calls for applications, and a final score may be awarded, where applicable.

Final evaluation score

0,0

Important note

The components for calculating the assessment score can be found in the selection criteria document mentioned below.

Selection criteria

The funding selection criteria to which this project and its final beneficiary were subject and its score can be found in detail on the Recuperar Portugal platform.

Project Selection Criteria

GeneLink

Beneficiaries

Intermediate beneficiaries

IAPMEI - AGÊNCIA PARA A COMPETITIVIDADE E INOVAÇÃO, I.P.

Contracted financing 30 thousand €

Beneficiaries

GHP - GLOBAL HEALTH PLATFORM, S.A.

Assigned funding 30 thousand €

Spent value 5 thousand €

Procurement

Beneficiaries representing public entities implement their project by signing one or more contracts with suppliers for goods or services through public procurement procedures.

To ensure and provide the utmost transparency in all these contracts, a list of the contracts that were signed under this project is available here, along with the information available on the Base.Gov platform. Please note that, according to the legislation in force at the time the contract was signed, some exceptions do not require the publication of the contracts signed on this platform, and, therefore, no information is available in such cases.